From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation

Eur J Med Chem. 2012 Jan;47(1):432-444. doi: 10.1016/j.ejmech.2011.11.012.

Bo Zhong ^# ¹, Xiaohan Cai ^# ¹, Snigdha Chennamaneni ¹, Xin Yi ¹, Lili Liu ², John J Pink ³, Afshin Dowlati ², Yan Xu ¹, Aimin Zhou ¹ ⁴, Bin Su ¹ ⁴

Affiliations

1 Department of Chemistry, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, OH, 44115, USA.
2 Division of Hematology and Oncology, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
3 Division of General Medical Sciences-Oncology, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
4 Center for Gene Regulation in Health and Disease, College of Sciences & Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, OH, 44115, USA.
# Contributed equally.

PMID: 22119125 DOI: 10.1016/j.ejmech.2011.11.012

Abstract

Cyclooxygenase-2 (COX-2) inhibitor nimesulide inhibits the proliferation of various types of Cancer cells mainly via COX-2 independent mechanisms, which makes it a good lead compound for anti-cancer drug development. In the presented study, a series of new nimesulide analogs were synthesized based on the structure-function analysis generated previously. Some of them displayed very potent anti-cancer activity with IC(50)s around 100 nM-200 nM to inhibit SKBR-3 breast Cancer cell growth. CSUOH0901 (NSC751382) from the compound library also inhibits the growth of the 60 Cancer cell lines used at National Cancer Institute Developmental therapeutics Program (NCIDTP) with IC(50)s around 100 nM-500 nM. Intraperitoneal injection with a dosage of 5 mg/kg/d of CSUOH0901 to nude mice suppresses HT29 colorectal xenograft growth. Pharmacokinetic studies demonstrate the good bioavailability of the compound.

Name
Email *

	Sorry, but the email address you supplied was invalid.